Introduction
============

With progression in cancer treatment, the survival rate of patients has increased globally in 2012 ([@b1-ol-0-0-9294],[@b2-ol-0-0-9294]). In the USA, the number of people with a cancer diagnosis was \~14.5 million in 2014 ([@b3-ol-0-0-9294]). Based on the Surveillance, Epidemiology and End Results (SEER) program, cancer survivors have a higher risk of second primary cancer (SPC) compared with the general population ([@b4-ol-0-0-9294]). Despite the medical progression achieved and the advances in locoregional control, continual SPC is one of the factors that impede the improvement of survival rate of patients with cancer ([@b5-ol-0-0-9294]); therefore, SPC is an important prognostic factor for patients with head and neck cancer (HNC) ([@b6-ol-0-0-9294]). Furthermore, SPC more frequently develops following HNC, compared with the general population ([@b5-ol-0-0-9294],[@b7-ol-0-0-9294]). 2-\[18F\]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) is primarily used to examine lymph nodes, the initial stage of HNC, treatment responses, unknown primary cancer (PCs) types and relapses or metastases ([@b8-ol-0-0-9294]--[@b11-ol-0-0-9294]); however, there is no accurate FDG-PET protocol to detect SPC over a long-term follow-up period subsequent to HNC treatment. In the present study, a rare case of triple PC, including well to moderately differentiated squamous cell carcinoma (SCC) of the mandible, axillary cutaneous poorly differentiated SCC and adenocarcinoma (AC) of the prostate, was described. The prostate tumor was incidentally detected by FDG-PET. The aim of the present study was to discuss the necessity of FDG-PET as a protocol of postoperative follow-up.

Case report
===========

Written informed consent was obtained from the patient for the publication of this case report and the accompanying images. The report was submitted for ethical review to the Ethics Committee of the University of the Ryukyus (Okinawa, Japan), which waived the requirement for review per institutional protocol due to the study not containing content that requires ethical approval. The Ethics Committee approved the submission and publication of the manuscript.

A 70-year-old man was evaluated and treated for cancer of the right mandible in September 2012 at the Department of Oral and Maxillofacial Surgery, University Hospital of the Ryukyus (Okinawa, Japan). The disease was initially considered to be benign or an inflammation in the radiolucent area around the wisdom teeth, and the patient underwent extraction of the right third molar and curettage (with histological test) at a different clinic (Nanbu Tokushukai Hospital, Okinawa, Japan); however, the histopathological examination at this clinic demonstrated well to moderately differentiated SCC, according to the World Health Organization Classification of Tumours ([@b12-ol-0-0-9294]) ([Fig. 1](#f1-ol-0-0-9294){ref-type="fig"}). Histopathological examination was conducted with hematoxylin and eosin staining. In brief, resected tissues were fixed in 20% formalin for \~24 h at room temperature. Subsequently, slides were washed with xylene for 9 min, then dexylened with 100, 95, 80 and 70% ethanol for 20, 10, 10 and 10 times, respectively. Slides were then stained with hematoxylin for 10 min, and washed with tap water for 3 min. Subsequently, slides were washed with 0.5% hydrochloric acid alcohol once and washed with tap water for 5 min. Following this, slides were stained with eosin for 6 min and slides were dehydrated with 95 and 100% ethanol for 10 and 40 times, respectively. Additionally, slides were immersed in xylene 30 times and cover glass was placed on the slides. All of the methods were at room temperature, and then examined using a light microscope at ×200 magnification. Subsequently, the patient was referred to the University Hospital of the Ryukyus. Physical examination indicated slight swelling of the gum around the extraction socket. No specific lesion was located in the mouth, and no palpable lymph node enlargement was evident in the head or neck region. The patient had no history of cancer and had never undergone radiation therapy or chemotherapy. Additionally, the patient had been a moderate smoker in his 20s and was a moderate drinker. The family history included gastric cancer in two brothers. The patient also suffered from well-controlled hypertension, reflux esophagitis, hyperuricemia, sensorineural hearing loss, cerebral infarction and dyslipidemia.

Contrast-enhanced computed tomography (CT), contrast-enhanced magnetic resonance imaging (MRI) and FDG-PET were used to examine the mandible cancer stage. The CT results demonstrated bone resorption in the right mandible and tumor invasion was suspected ([Fig. 2](#f2-ol-0-0-9294){ref-type="fig"}), whereas no lesions were observed in the cervical lymph nodes, lungs, bones or liver. The MRI results indicated high-signal intensity around the margins of the curettaged area; however, no other lesions were located in the head and neck region. FDG-PET was used to examine the stage of SCC and revealed increased FDG uptake \[maximum standardized uptake value (SUVmax), 11.9\] in the right mandible. Additionally, no other potential cancer areas were located in the rest of the body. An upper gastrointestinal endoscopy demonstrated no abnormal data. As a result, the patient was diagnosed with mandibular SCC (T4N0M0, stage IVa), according to the Union for International Cancer Control Tumor-Node-Metastasis classification, 7th edition ([@b13-ol-0-0-9294]).

The patient received 6 cycles of bleomycin chemotherapy preoperatively (total dose, 90 mg), as described previously ([@b14-ol-0-0-9294],[@b15-ol-0-0-9294]). In October 2012, the patient underwent segmental mandibulotomy and reconstructive grafting (non vascularized bone grafting), ipsilateral supraomohyoid neck dissection and tracheotomy. A pathological examination demonstrated SCC of the submaxilla, with venous invasion but no lymphatic invasion. Furthermore, bone invasion was present, but the surgical margins were negative. Cervical lymph nodes exhibited no evidence of cancer. Following surgery, a salivary fistula of the parotid region persisted. The patient then underwent postoperative radiation (total dose, 20 Gy in 10 fractions over \~3 weeks). Resolution of the salivary fistula using low-dose radiation therapy was attempted ([@b16-ol-0-0-9294],[@b17-ol-0-0-9294]), and notably, the fistula was successfully resolved. Although a number of studies have reported a lower success rate of radiotherapy following the reconstruction of a non-vascularized bone graft ([@b18-ol-0-0-9294],[@b19-ol-0-0-9294]), the radiotherapy for those patients is not contraindicated in the National Comprehensive Cancer Network guideline ([@b20-ol-0-0-9294]); therefore, a low-dose radiation was selected to resolve the salivary fistula of the parotid region ([@b17-ol-0-0-9294]). Surgical site infection did occur, and the grafted bone and titan plate were surgically removed 4 months after the implantation. Subsequently, no clinical or radiological signs of mandible cancer recurrence/metastasis or infection in the head and neck region or the lungs were observed.

The patient developed skin cancer (second type) and prostate cancer (PRC) (third type) 3 years after the mandible (first type) cancer treatment. A nodule on the left axillary cutaneous lesion was noted by the patient in July 2015. In April 2016, the nodule (18×10×7 mm in size) was resected at a different hospital (Chibana Clinic, Okinawa, Japan) and pathologically diagnosed as poorly differentiated SCC of the skin, according to the World Health Organization Classification of Tumours ([@b21-ol-0-0-9294]). A pathological examination demonstrated poorly differentiated SCC, with positive margins (data not shown). Pathological examination was conducted with hematoxylin and eosin staining. In brief, resected tissues were fixed in 10% formalin for \~24 h at room temperature. Subsequently, slides were washed with xylene for 15 min, then dexylened with 100, 80 and 50% ethanol for 2, 1 and 1 min, respectively. Subsequently, slides were washed with tap water for 2 min. Following this, slides were washed with distilled water for 30 sec. Slides were then stained with hematoxylin for 4 min and washed with tap water for 6 min. Additionally, slides were washed with distilled water for 30 sec. Subsequently, slides were stained with eosin for 3 min and slides were dehydrated with 100% ethanol for 4 min. Following this, slides were immersed in xylene for 8 min and cover glass was placed on the slides. All of the methods were at room temperature, and then examined using a light microscope at ×200 magnification. Subsequently, the patient was referred to University Hospital of the Ryukyus for further examination and treatment. Contrast-enhanced CT and FDG-PET were performed to evaluate the skin cancer stage. There was no accumulation in the axillary skin, axillary lymph nodes, lungs, and head and neck region; however, FDG uptake was observed in the prostate (SUVmax, 4.61) ([Fig. 3](#f3-ol-0-0-9294){ref-type="fig"}). The patient had a prostate-specific antigen (PSA) level of 19.87 ng/ml (normal range, 0--3.53 ng/ml). Due to the absence of clinical symptoms of 'non-head and neck, lung and esophagus cancer', the PSA or carcinoembryonic antigen test was not performed prior to the PET examination of the skin cancer. Notably, the SPC incidence of this cancer type (non-head and neck, lung and esophagus cancer) is low in patients with HNC ([@b22-ol-0-0-9294]). Additional resection of skin (second) cancer was first performed in June 2016 at the University Hospital of the Ryukyus and poorly differentiated SCC was resected. Pathological examination was conducted with hematoxylin and eosin staining. In brief, resected tissues were fixed in 10% formalin for \~24 h at room temperature. Subsequently, slides were washed with xylene for 9 min, then dexylened with 100, 95 and 70% ethanol for 3, 1 and 1 min, respectively. Subsequently, slides were washed with tap water for 3 min. Slides were then stained with hematoxylin for 4 min, and washed with tap water for 3 min. Following this, slides were dehydrated with 95% ethanol for 1 min. Subsequently, slides were stained with eosin for 3 min and slides were washed with 95 and 100% ethanol for 2 and 8 min, respectively. Subsequently, slides were immersed in xylene for 12 min and cover glass was placed on the slides. All of the methods were at room temperature, and then examined using a light microscope at ×100 magnification ([Fig. 4](#f4-ol-0-0-9294){ref-type="fig"}). Following the resection of the second cancer, a guided percutaneous needle biopsy of the prostate lesion was performed in August 2016 at the University Hospital of the Ryukyus, which indicated a diagnosis of AC (Gleason score 4+5), according to Gleason and Mellinger ([@b23-ol-0-0-9294]). Laparoscopic prostatectomy and pelvic lymphadenectomy was then performed for the PRC (third type) in October 2016 at the University Hospital of the Ryukyus. Pathological data demonstrated positive pT4 (bladder) invasion ([Fig. 5](#f5-ol-0-0-9294){ref-type="fig"}). Pathological examination was conducted with hematoxylin and eosin staining. In brief, resected tissues were fixed in 10% formalin for \~24 h at room temperature. Subsequently, slides were washed with xylene for 9 min, then dexylened with 100, 95 and 70% ethanol for 3, 1 and 1 min, respectively. Subsequently, slides were washed with tap water for 3 min. Slides were then stained with hematoxylin for 4 min and washed with tap water for 3 min. Following this, slides were dehydrated with 95% ethanol for 1 min. Subsequently, slides were stained with eosin for 3 min and slides were washed with 95 and 100% ethanol for 2 and 8 min, respectively. Following this, slides were immersed in xylene for 12 min and cover glass was placed on the slides. All of the methods were at room temperature, and then examined using a light microscope at ×200 magnification. Negative lymphatic (D2-40) and vascular (by Victoria blue-hematoxylin and eosin staining) invasion, positive perineural (S-100) invasion and positive margins, but no lymph node metastasis was found. Victoria blue-hematoxylin and eosin staining was conducted. In brief, resected tissues were fixed in 10% formalin for \~24 h at room temperature. Subsequently, slides were washed with xylene for 9 min, and then dexylened with 100, 95 and 70% ethanol for 6, 3 and 3 min, respectively. Slides were then stained with Victoria blue overnight at room temperature, the remainder of Victoria blue was removed with 70% ethanol and then washed with tap water. Subsequently, slides were washed with xylene for 3 min, and then washed with tap water for 3 min. Following this, slides were stained with hematoxylin for 3 min. Subsequently, washed with tap water for 3 min and dehydrated with 95% ethanol 20 times. Following this, slides were stained with eosin for 3 min, and then dehydrated with 100% ethanol for 4 min. Slides were then immersed in xylene for 12 min, and cover glass was placed on the slides. All of the methods were at room temperature, and then examined using a light microscope at ×200 magnification. However, in February 2017, follow-up PSA indicated the high PSA level of 35.67 ng/ml (normal range, 0--3.53 ng/ml) was elevated, and subsequent CT and FDG-PET demonstrated recurrence of the PRC, accompanied with lymph node metastasis of the left axillary and pelvic regions, and suspected multiple liver metastases (the liver lesion was then examined by fine-needle biopsy in April 2017 and no cancerous lesions were histologically located). Axillary lymph node dissection was performed in July 2017, and the lymph nodes were histologically diagnosed as SCC metastases. The patient was treated with chemotherapy \[from March 2017, docetaxel (60 mg/m^2^) was intravenously administered 10 times, and degarelix were administered subcutaneous injections into the abdominal region 14 times (240 mg once in March 2017 and then 80 mg 13 times)\] for the liver, pelvic and prostate regions. The time between administration of the two drugs was 4 or 5 weeks. The lesions gradually diminished at the time of writing, therefore his prognosis cannot be stated, and further treatment of the chemotherapy (identical dose of docetaxel and degarelix) are planned. Based on the aforementioned lesions, the patient was diagnosed with 'triple PCs', according to the criteria by Warren and Gates ([@b24-ol-0-0-9294]), and the skin and PRCs were synchronous, according to the criteria by Moertel *et al* ([@b25-ol-0-0-9294]). The skin cancer (poorly differentiated SCC) was not considered the metastasis of the mandible cancer (well to moderately differentiated SCC), according to the criteria by Warren and Gates ([@b24-ol-0-0-9294]).

Discussion
==========

There are two important points in the present report: Firstly, to the best of our knowledge, the combination of triple PCs (well-differentiated SCC of the mandible, axillary cutaneous poorly differentiated SCC and prostate AC) has not been previously reported; secondly, to detect SPC, we suggest that FDG-PET should be used for the long-term follow-up of patients with HNC.

Based on the aforementioned lesions, the patient in the present case was diagnosed with triple PCs according to the criteria suggested by Warren and Gates in 1932 ([@b24-ol-0-0-9294]), and the skin and PRCs were synchronous according to the criteria defined by Moertel *et al* in 1961 ([@b25-ol-0-0-9294]). A systematic literature search of PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>) and Google Scholar (<https://scholar.google.co.jp/>) articles published between 1932, when the SPC criteria was firstly defined ([@b24-ol-0-0-9294]), and 2017 was performed. The databases were searched using the following terminological combinations (one term used from each category): i) Any region of the head and neck, including oral cavity, oral, mouth, oral floor, tongue, lip, soft plate, gingiva, buccal, maxillary, mandibular, tonsil, neck, face, cheek, salivary grand, parotid gland, sublingual gland, submandibular gland, nose, nasal cavity, paranasal sinus, nasopharynx, larynx, oropharynx, mesopharynx, hypopharynx, glottis, thyroid, ear; ii) prostate; and iii) SPC terms, including second primary cancer, second primary malignancy, second primary tumor, multiple primary cancer, multiple primary neoplasm, multiple primary malignancies, multiple primary malignant, triple primary, triple cancer, quadruple primary, quadruple cancer, quintuple primary, quintuple cancer, sextuple primary, sextuple cancer, septuple primary, septuple cancer, octuple primary, octuple cancer, nonuple primary, or nonuple cancer. A report containing more than decuple primary cancer types, including PRC, could not be located. English articles were then searched using the aforementioned terms. This resulted in the identification of 23 cases of patients with multiple (triple or more) cancer types, including HNC and PRC ([@b25-ol-0-0-9294]--[@b39-ol-0-0-9294]) ([Table I](#tI-ol-0-0-9294){ref-type="table"}). The study by Gordon ([@b26-ol-0-0-9294]) was located by non-systematic literature research, using Google Scholar and the term 'synchronous primary carcinoma.' However, the current combination was not found. The most frequent sites of incident of SPC following HNC are the head and neck again, the lungs and the esophagus ([@b7-ol-0-0-9294],[@b22-ol-0-0-9294]); while SPC of the skin or prostate is uncommon. Although a number of risks of SPC have been suggested to date, the risk of SPC is unclear ([@b40-ol-0-0-9294]). As the combination of triple PCs in the present study was unique, the risk factors may have included the administration of preoperative chemotherapy ([@b41-ol-0-0-9294]) and radiation postoperatively for index mandible cancer ([@b41-ol-0-0-9294],[@b42-ol-0-0-9294]), the fact that the patient was a current drinker ([@b41-ol-0-0-9294],[@b43-ol-0-0-9294]), a family history of gastric cancer in two brothers ([@b44-ol-0-0-9294]) and finally, the patient being a former smoker ([@b43-ol-0-0-9294],[@b45-ol-0-0-9294]). The association between being a former smoker and secondary cancer risk in cancer survivors is unclear in the present case due to the cessation of smoking more than 40 years previously. Shiels *et al* ([@b45-ol-0-0-9294]) demonstrated that being a former smoker resulted in a higher SPC risk compared with the risk for those who had never smoked. Based on the aforementioned data, all factors for SPC risk in the current case should be carefully considered. Rose *et al* ([@b6-ol-0-0-9294]) analyzed 34,568 patients with non-metastatic SCC of HNC, based on SEER data, and reported that patients with HNC are at a high risk of SPC. The 5-year cumulative all-cause fatality rate, HNC-specific fatality rate, SPC fatality rate and non-cancer fatality rate were 51.3, 23.8, 14.6 and 13.0%, respectively. Additionally, the 10-year cumulative rate of SPC mortality reached 20% ([@b6-ol-0-0-9294]). As a result, mortality due to SPC is high and persistent over a long term, and contributes to the poor prognosis of SCC in patients with HNC ([@b6-ol-0-0-9294]). Other previous studies have also indicated that even in long-term cancer survivors, SPC following HNC poses a high risk ([@b39-ol-0-0-9294],[@b42-ol-0-0-9294],[@b46-ol-0-0-9294]). Furthermore, SPC more frequently develops in various sites in patients with HNC, compared with the SPC occurrence of the general population ([@b5-ol-0-0-9294],[@b7-ol-0-0-9294]); therefore, clinicians should give more focus to SPC following HNC treatment, and a more accurate protocol should be established.

We suggest that FDG-PET could be used for detecting SPCs in the long-term follow-up of patients with HNC. To date, there is no accurate protocol of FDG-PET for the follow-up of patients with HNC. In the present case, PRC (third type) was determined during the preoperative FDG-PET for skin (second type) cancer. The PRC (third type) was not determined during the first follow-up period of 3 years, between the mandible (first type) cancer treatment and the skin (second type) cancer occurrence. Contrast-enhanced CT was performed from the head to the lungs routinely during the follow-up subsequent to the HNC treatment; if FDG-PET had been performed as a routine follow-up tool of mandible cancer, the PRC may have been detected earlier. Cancer of the oral cavity and skin are relatively simple to detect due to the lesions being observed directly. Conversely, as PRC is asymptomatic in the early stages ([@b47-ol-0-0-9294]) and is an internal disease, it is frequently incidentally detected. In order to confirm the diagnosis method of PRC of those patients, the cases in [Table I](#tI-ol-0-0-9294){ref-type="table"} were further reviewed and the manner in which the subsequent PRC was detected is indicated ([@b28-ol-0-0-9294],[@b29-ol-0-0-9294],[@b31-ol-0-0-9294],[@b33-ol-0-0-9294]--[@b35-ol-0-0-9294],[@b37-ol-0-0-9294],[@b38-ol-0-0-9294]) ([Table II](#tII-ol-0-0-9294){ref-type="table"}). Of the 9 patients in which PRC was diagnosed, including the present case, PRC was detected by a serum test in 2, incidentally by surgery of the other tumor in 2, by FDG-PET in 2 and by clinical symptoms in 1 (PRC detection in 2 patients was not described). Similar to the present case, Testori *et al* ([@b37-ol-0-0-9294]) incidentally detected lung cancer using FDG-PET ([@b37-ol-0-0-9294]). Notably, among the cases in [Table II](#tII-ol-0-0-9294){ref-type="table"}, 5/7 patients presented with no subjective symptoms of PRC and were incidentally diagnosed with cancer. Additionally, in the SEER study, the incidence of secondary PRC within 1 year of HNC was only 0.3% among 26,258 male patients with oral and pharyngeal (tongue, mouth, tonsil, oropharyngeal and hypopharyngeal) cancer ([@b4-ol-0-0-9294]).

Patients with cancer should be carefully followed up in order to detect SPC for the following reasons: i) patients with cancer have a higher risk for SPC a long time period after PC compared with the general population ([@b42-ol-0-0-9294]); ii) as aforementioned, SPC more frequently develops in various sites in the body following HNC ([@b5-ol-0-0-9294],[@b7-ol-0-0-9294]); iii) PRC should be detected at an early stage when it is asymptomatic, due to this condition demonstrating a poor prognosis at advanced stages ([@b48-ol-0-0-9294]) \[for patients with localized stage PRC, the 5-year relative survival rate is \~100%; by contrast, for patients with advanced (distant) stage PRC, the rate declines to 28% ([@b49-ol-0-0-9294])\]; and iv) PRC accounted for \~20% of new cancer cases in males in the USA in 2016 ([@b50-ol-0-0-9294]). In the USA, among males, the most prevalent cancer in 2016 was PRC, which was recorded in 3.3 million cases ([@b49-ol-0-0-9294]); therefore, long-term follow-up to detect PRC following HNC treatment is required. Yamashita *et al* ([@b43-ol-0-0-9294]) routinely performed FDG-PET/CT scans once every 6--12 months for 5 years in the follow-up period following the initial cancer treatment of 434 patients with newly diagnosed HNC, and determined that 12% of patients had synchronous SPC and 24% of patients had metachronous SPC. It is important to utilize FDG-PET for screening SPC during follow-up of HNC, as well as during preoperative cancer staging ([@b43-ol-0-0-9294],[@b51-ol-0-0-9294]). Compared with CT or MRI, PET/CT has the advantage of evaluating SPC not only at initial staging of first HNC ([@b51-ol-0-0-9294]), but also postoperative follow-up, similar to the present case, due to PET/CT can evaluate the entire body range; however, there is no accurate protocol for detecting SPC for the long-term follow-up of HNC to date. FDG-PET/CT has an important role in the management of patients with HNC, in order to diagnose long-term surveillance of recurrence or metastasis ([@b11-ol-0-0-9294]). For patients with HNC, FDG-PET/CT is generally performed at ≥6 months after the initial therapy ([@b11-ol-0-0-9294]); however, there are numerous studies regarding PET/CT that have reported a range of follow-up periods ([@b9-ol-0-0-9294],[@b36-ol-0-0-9294],[@b43-ol-0-0-9294],[@b52-ol-0-0-9294]), indicating that the optimal follow-up period has yet to be defined. In the present case, second primary PRC was detected 3 years after the initial HNC. Although PET/CT can be performed for extended follow-ups, it has certain disadvantages and risks, including the following: The scan may provide false-positive results ([@b9-ol-0-0-9294]); patients with diabetes mellitus cannot undergo PET/CT ([@b53-ol-0-0-9294]); PET/CT sensitivities depend on the body site ([@b54-ol-0-0-9294]); and finally, inflammatory lesions, metal artifacts or benign lesions can cause difficulties in performing PET/CT ([@b55-ol-0-0-9294]). Furthermore, the complications caused by the exposure to X-rays whilst performing PET/CT should be considered ([@b53-ol-0-0-9294]). Additionally, the decision to perform the examination differs among nations, indicating that clinicians should consider the characteristics of the health care system of each country.

There are several limitations in the present study, including the fact that the conclusions are based on a single case report, which limits the generalizability, and that the present combination of triple cancer was researched using PubMed and Google scholar, which are major search services, but other search engines were not used. For the present case, further studies may provide beneficial information for detecting SPCs, including PRC, following the treatment of HNC.

In conclusion, a rare case of triple PCs was described in the present study. We suggest that FDG-PET should be performed to detect hidden SPC, such as PRC, for the long-term follow-up of patients with HNC, particularly in cases where risk factors are present. SPC should be detected early in order to maximize positive patient outcomes.
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SPC

:   second primary cancer

FDG-PET

:   2-\[18F\]-fluoro-2-deoxy-D-glucose-positron emission tomography

SEER

:   Surveillance, Epidemiology and End Results

HNC

:   head and neck cancer

PC

:   primary cancer

SCC

:   squamous cell carcinoma

AC

:   adenocarcinoma

CT

:   computed tomography

MRI

:   magnetic resonance imaging

SUVmax

:   maximum standardized uptake value

PSA

:   prostate-specific antigen

PRC

:   prostate cancer

![Histological examination of the mandible tissue by hematoxylin and eosin staining. Atypical squamous cells and cancer pearls are observed in the alveolar bone of the mandible, with intercellular bridges (arrow), which are characteristics of well-differentiated squamous cell carcinoma. Magnification, ×200; scale bar, 100 µm.](ol-16-04-5249-g00){#f1-ol-0-0-9294}

![Contrast-enhanced computed tomography results indicating resorption in the right mandible and suspected tumor invasion (arrow) (axial section).](ol-16-04-5249-g01){#f2-ol-0-0-9294}

![Preoperative use of 2-\[18F\]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (axial section). Metabolic activity was detected in the prostate (maximum standardized uptake value, 4.61) (arrow).](ol-16-04-5249-g02){#f3-ol-0-0-9294}

![Histological examination of the skin tissue by hematoxylin and eosin staining. Irregular nests and cords composed of atypical squamous cell without keratinization infiltrate the dermis and subcutaneous tissue, and spindle-shaped cells are observed (arrow), which are characteristics of poorly differentiated squamous cell carcinoma. Magnification, ×100; scale bar, 100 µm.](ol-16-04-5249-g03){#f4-ol-0-0-9294}

![Histological examination of the prostate tissue by hematoxylin and eosin staining. Solid strands without glandular lumina invade the stroma (arrow). Magnification, ×200; scale bar, 100 µm.](ol-16-04-5249-g04){#f5-ol-0-0-9294}

###### 

Cases exhibiting triple or greater primary cancer of multiple types, including head and neck, and prostate cancer.

                                                                        Order of sites exhibiting the occurrence of multiple primary cancer                                                                     
  --------------------------------------------------------------------- --------------------------------------------------------------------- ------------------ ------------- ------------ ------- ----------- ----------------------
  Gordon (1948)                                                         PRC                                                                   Lung               Thyroid                                        ([@b26-ol-0-0-9294])
  Goodner and Watson (1956)                                             Soft plate                                                            Esophagus          PRC                                            ([@b27-ol-0-0-9294])
  Moertel *et al*^[a](#tfn1-ol-0-0-9294){ref-type="table-fn"}^ (1961)   Colon                                                                 Lip                PRC                                            ([@b25-ol-0-0-9294])
                                                                        Kidney                                                                Mouth              PRC                                            ([@b25-ol-0-0-9294])
                                                                        Lip                                                                   Lung               PRC                                            ([@b25-ol-0-0-9294])
                                                                        Lung                                                                  PRC                Thyroid                                        ([@b25-ol-0-0-9294])
                                                                        Lip                                                                   Skin               PRC                                            ([@b25-ol-0-0-9294])
                                                                        Mouth                                                                 Mouth              PRC                                            ([@b25-ol-0-0-9294])
                                                                        Lip                                                                   Mouth              PRC                                            ([@b25-ol-0-0-9294])
  Bittorf *et al* (2001)                                                PRC                                                                   Colorectum         Oral cavity                                    ([@b28-ol-0-0-9294])
                                                                        Thyroid                                                               UB                 PRC                                            ([@b28-ol-0-0-9294])
  Rho *et al* (2002)                                                    Vocal cord                                                            Bowen\'s disease   PRC           Laryngeal                        ([@b29-ol-0-0-9294])
  Rai *et al* (2007)                                                    PRC                                                                   Kidney             Thyroid                                        ([@b30-ol-0-0-9294])
  Jaudah *et al* (2008)                                                 Thyroid                                                               PRC                Renal                                          ([@b31-ol-0-0-9294])
  Yamashita *et al* (2010)                                              PRC                                                                   Gastric            Laryngeal                                      ([@b32-ol-0-0-9294])
  Salem *et al* (2012)                                                  PRC                                                                   Nasopharyngeal     Lung                                           ([@b33-ol-0-0-9294])
                                                                        Renal                                                                 Nose               Auricle       PRC          Colon               ([@b33-ol-0-0-9294])
  Guven *et al* (2014)                                                  Bladder                                                               PRC                Thyroid                                        ([@b34-ol-0-0-9294])
  Mukaiyama *et al* (2014)                                              Glottis                                                               Renal pelvis       UB            Oral floor   PRC     Esophagus   ([@b35-ol-0-0-9294])
  Mohammed *et al* (2015)                                               PRC                                                                   UB                 Thyroid                                        ([@b36-ol-0-0-9294])
  Testori *et al* (2015)                                                Lung                                                                  Oropharynx         Large bowel   PRC                              ([@b37-ol-0-0-9294])
  Pastore *et al* (2015)                                                Kidney                                                                Oropharynx         PRC                                            ([@b38-ol-0-0-9294])
  Adel *et al* (2016)                                                   Buccal                                                                Lip                Gum           PRC                              ([@b39-ol-0-0-9294])
  Present case                                                          Mandible                                                              Axillary skin      PRC                                            --

Order of incidence was unknown. PRC, prostate cancer; UB, urinary bladder.

###### 

Method of detecting subsequent PRC from cases of [Table I](#tI-ol-0-0-9294){ref-type="table"}.

  Author (year)              Interval between first cancer and subsequent PRC   Method of detecting PRC                                                                         Subjective symptoms of PRC                                                     (Refs.)
  -------------------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ----------------------
  Bittorf *et al* (2001)     11 years                                           NA                                                                                              NA                                                                             ([@b28-ol-0-0-9294])
  Rho *et al* (2002)         3 years                                            Serum tumor marker test to rule out hidden cancer following the diagnosis of Bowen\'s disease   None                                                                           ([@b29-ol-0-0-9294])
  Jaudah *et al* (2008)      10 years                                           Urinary symptom                                                                                 Urinary symptom                                                                ([@b31-ol-0-0-9294])
  Salem *et al* (2012)       5 years                                            NA                                                                                              NA                                                                             ([@b33-ol-0-0-9294])
  Guven *et al* (2014)       Simultaneous                                       Incidentally determined in BC surgery                                                           Hematuria and frequent urination, which were considered to be a result of BC   ([@b34-ol-0-0-9294])
  Mukaiyama *et al* (2014)   3 years 9 months                                   Incidentally determined in recurrent BC surgery                                                 None                                                                           ([@b35-ol-0-0-9294])
  Testori *et al* (2015)     Simultaneous                                       Incidentally detected by FDG-PET for suspected lung cancer                                      None                                                                           ([@b37-ol-0-0-9294])
  Pastore *et al* (2015)     7 months                                           Serum tumor marker test for follow-up after kidney cancer treatment                             None                                                                           ([@b38-ol-0-0-9294])
  Present case               3 years 8 months                                   Incidentally detected by FDG-PET to determine the preoperative axillary cancer staging          None                                                                           --

PRC, prostate cancer; NA, not applicable; BC, bladder cancer; FDG-PET, 2-\[18F\]-fluoro-2-deoxy-D-glucose-positron emission tomography.
